You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Mounjaro® (tirzepatide) be used in people who have undergone surgery for weight loss?
Tirzepatide has not been studied in people who have undergone any type of bariatric surgery.
See important safety information, including boxed warning, in the attached prescribing information.
Weight Loss Surgeries
Eli Lilly and Company cannot provide a recommendation on whether to use tirzepatide in a patient who have any type of bariatric surgery either previous or planned. The healthcare practitioner may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors in developing a treatment plan. The healthcare practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
Lilly has no information on the use of tirzepatide in people who have undergone any type of bariatric surgery. Patients were excluded from tirzepatide clinical trials if they had prior or planned bariatric surgery (ie, sleeve gastrectomy, gastric bypass, or gastric band (Lap-Band®).1
Although some independent, non-Lilly, studies on tirzepatide and bariatric surgery exist, Lilly
- has not sponsored or reviewed these studies,
- is not affiliated with these studies
- cannot confirm their scientific merit, clinical relevance, or generalizability.
Enclosed Prescribing Information
Reference
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: November 28, 2025